Dr. Lal PathLabs announced its audited standalone and consolidated financial results for the quarter and full fiscal year ended March 31, 2026, at its Board of Directors meeting held on April 30, 2026. The company reported a 12.2% increase in consolidated annual revenue from operations to INR 27,629 million, driven by volume growth and strategic expansion. The board also approved several significant corporate actions, including the incorporation of a wholly owned subsidiary in Dubai and the acquisition of Shahbazkers Diagnostic Centre Private Limited.

FY26 Consolidated Financial Performance

For the full year ended March 31, 2026, consolidated revenue from operations grew to INR 27,629 million from INR 24,614 million in the previous year. Total consolidated income for the year stood at INR 28,642 million compared to INR 25,548 million in the prior year. Profit for the year (consolidated) came in at INR 5,098 million against INR 4,922 million previously, while total comprehensive income reached INR 5,150 million. Basic and diluted earnings per share (consolidated) for the year stood at INR 30.24 and INR 30.20, respectively.

For Q4 FY26 (three months ended March 31, 2026), consolidated revenue from operations was INR 7,027 million compared to INR 6,026 million in the corresponding quarter of the previous year. Consolidated profit before tax for Q4 FY26 stood at INR 1,601 million, with profit for the quarter at INR 1,322 million. An exceptional item of INR 301 million was recorded in Q3 FY26 (three months ended December 31, 2025) on account of the impact of Labour Codes notified by the Government of India on November 21, 2025, reflecting increases in gratuity and leave liabilities arising from the new unified labour framework.

FY26 Standalone Financial Performance

On a standalone basis, revenue from operations for the full year ended March 31, 2026 was INR 26,476 million, up from INR 23,516 million in the previous year. Standalone profit for the year was INR 5,082 million compared to INR 4,973 million previously, with total comprehensive income at INR 5,132 million. Standalone basic and diluted EPS for the year stood at INR 30.45 and INR 30.40, respectively.

The consolidated balance sheet as at March 31, 2026 reflected total assets of INR 31,460 million, up from INR 27,168 million as at March 31, 2025. Total equity stood at INR 25,413 million, with equity attributable to owners of the company at INR 25,082 million. Cash and cash equivalents at the end of the year were INR 2,428 million on a consolidated basis and INR 2,344 million on a standalone basis. Net cash generated from consolidated operating activities for the year was INR 6,357 million.

Dividend and Capital Actions

The board recommended a final dividend of INR 4 per equity share (at 40% on a face value of INR 10 per share) for the financial year ended March 31, 2026, subject to shareholder approval at the ensuing Annual General Meeting. The record date for the final dividend has been fixed as June 26, 2026. Including previously declared interim dividends of INR 6, INR 7, and INR 3.5 per share, the total dividend for the year amounts to INR 20.5 per equity share. Additionally, the board approved the allotment of 82,750 equity shares under the Employee Stock Option Plan 2022, increasing the paid-up equity share capital to INR 1,67,63,77,700, divided into 16,76,37,770 equity shares of INR 10 each. The company had earlier allotted 8,37,75,510 bonus equity shares in December 2025 in a 1:1 ratio, with December 19, 2025 as the record date.

FY27 Management Guidance

Management has provided a positive outlook for FY27, projecting early to mid-teens revenue growth in the range of 13–15%, supported by the maturation of recent infrastructure investments. EBITDA margins are guided at 27–28%. Capital expenditure for FY27 is planned in the range of INR 100 crore to INR 120 crore. Management indicated that while a price hike is not immediate, it remains a possibility depending on market conditions, with the focus remaining on reinvesting in the business to drive growth.

Strategic and Corporate Developments

The board approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), incorporated in Maharashtra on July 30, 2021, for a cash consideration not exceeding INR 20 crore. SDCPL, which operates in the diagnostics services space, reported turnover of INR 6.11 crore in FY26, INR 5.96 crore in FY25, and INR 5.42 crore in FY24. The transaction is expected to be completed by May 31, 2026, and is aimed at strengthening the company's presence in Mumbai. Post-acquisition, SDCPL will become a wholly owned subsidiary. The board also approved the incorporation of a wholly owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, United Arab Emirates, subject to necessary regulatory and statutory approvals. The proposed entity intends to strategically invest in diagnostics and allied activities, including exploring potential acquisitions, tie-ups, or joint ventures.

During the year, the company added 14 new labs and over 1,100 collection centers. The preventive healthcare brand Swasthfit contributed 27% to total revenue in FY26. The company also launched Sovaaka, a premium wellness brand offering AI-powered precision health screening. The 32nd Annual General Meeting has been scheduled for Saturday, July 25, 2026, through Video Conferencing/Other Audio-Visual Means.

Governance and Leadership Updates

The board approved the re-appointment of (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for a period of five consecutive years commencing April 1, 2027, subject to shareholder approval at the ensuing AGM. Mr. Rajit Mehta was re-appointed as a Non-Executive Independent Director for five consecutive years commencing July 27, 2026, also subject to shareholder approval. Dr. Reena Nakra, Chief Scientific Officer, and Dr. Saloni Khera, Chief Lab Management Officer, were designated as Senior Management Personnel of the company effective April 30, 2026. M/s Ernst & Young LLP (EY) and M/s A.G. Agarwal & Associates were re-appointed as Internal Auditors and Cost Auditors, respectively, for the financial year 2026-27. The statutory audit for FY26 was conducted by Deloitte Haskins & Sells LLP, which issued an unmodified opinion on both the standalone and consolidated financial results.

Dr. Lal PathLabs Limited has successfully completed the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 01, 2026, pursuant to the terms and conditions of the Share Purchase Agreement. The company had earlier intimated the exchanges regarding this acquisition on April 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Following the completion of the acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly owned subsidiary of Dr. Lal PathLabs Limited. The disclosure requirements under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, were duly intimated in the earlier communication dated April 30, 2026.

Acquisition Details

The intimation was signed by Vinay Gujral, Company Secretary & Compliance Officer of Dr. Lal PathLabs Limited, and submitted to both the National Stock Exchange of India Limited and BSE Limited for necessary record. The official communication was digitally signed on May 01, 2026 at 19:16:40 +05'30.